LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Search

Aptevo Therapeutics Inc

Gesloten

4.87 9.19

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.46

Max

4.9

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+371.91% upside

Aptevo Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mei 2026, 23:31 UTC

Populaire aandelen

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mei 2026, 22:52 UTC

Belangrijke Marktbewegers

Osisko Shares Fall on Planned Convertible Notes Offering

20 mei 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mei 2026, 23:44 UTC

Winsten

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mei 2026, 23:35 UTC

Marktinformatie

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mei 2026, 23:30 UTC

Marktinformatie

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mei 2026, 23:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 mei 2026, 23:17 UTC

Marktinformatie

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mei 2026, 23:15 UTC

Marktinformatie

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mei 2026, 23:14 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mei 2026, 23:02 UTC

Marktinformatie

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Global Energy Roundup: Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 mei 2026, 22:51 UTC

Marktinformatie

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mei 2026, 22:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2026, 22:27 UTC

Marktinformatie

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mei 2026, 22:14 UTC

Marktinformatie

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mei 2026, 22:10 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mei 2026, 22:00 UTC

Winsten

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mei 2026, 21:38 UTC

Winsten
Acquisities, Fusies, Overnames

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mei 2026, 21:27 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mei 2026, 21:20 UTC

Winsten

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mei 2026, 21:19 UTC

Winsten

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mei 2026, 21:18 UTC

Winsten

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mei 2026, 21:17 UTC

Winsten

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mei 2026, 21:17 UTC

Winsten

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mei 2026, 21:17 UTC

Winsten

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mei 2026, 21:16 UTC

Winsten

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Vergelijking

Prijswijziging

Aptevo Therapeutics Inc Prognose

Koersdoel

By TipRanks

371.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 21 USD  371.91%

Hoogste 21 USD

Laagste 21 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Aptevo Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Financieel

$

help-icon Live chat